Article
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.
EMBO molecular medicine - 1 Oct 2013
Heier Christopher R, Damsker Jesse M, Yu Qing, Dillingham Blythe C, Huynh Tony, Van der Meulen Jack H, Sali Arpana, Miller Brittany K, Phadke Aditi, Scheffer Luana, Quinn James, Tatem Kathleen, Jordan Sarah, Dadgar Sherry, Rodriguez Olga C, Albanese Chris, Calhoun Michael, Gordish-Dressman Heather, Jaiswal Jyoti K, Connor Edward M, McCall John M, Hoffman Eric P, Reeves Erica K M, Nagaraju Kanneboyina
Abstract excerpt
Absence of dystrophin makes skeletal muscle more susceptible to injury, resulting in breaches of the plasma membrane and chronic inflammation in Duchenne muscular dystrophy (DMD). Current management by glucocorticoids has unclear molecular benefits and harsh side effects. It is uncertain whether therapies that avoid hormonal stunting of growth and development, and/or immunosuppression, would be more or less...
Topics
- Animals
- Anti-Inflammatory Agents
- Cell Line
- Cell Membrane
- Immunosuppressive Agents
- Lasers
- Mice
- Mice, Inbred mdx
- Muscular Dystrophies